301096 百诚医药
2026/06 - 中期2025/122024/122023/122022/12

盈利能力分析
净资产收益率 ROE (%)0.064-3.567-2.00410.5288.089
总资产报酬率 ROA (%)0.043-2.441-1.4278.2436.633
投入资产回报率 ROIC (%)0.045-2.575-1.5428.9667.062

边际利润分析
销售毛利率 (%)47.13039.50351.98265.52867.373
营业利润率 (%)0.247-13.132-4.28929.19331.057
息税前利润/营业总收入 (%)3.336-10.783-3.97226.97724.546
净利润/营业总收入 (%)0.523-13.333-6.60026.73531.946

收益指标分析
经营活动净收益/利润总额(%)-1,609.72377.19322.084102.44990.733
价值变动净收益/利润总额(%)670.55312.94415.506-0.036-2.081
营业外收支净额/利润总额(%)-3.8442.3094.624-0.4541.185

偿债能力分析
流动比率 (X)1.8451.6872.0091.9005.538
速动比率 (X)1.6281.4951.7781.7905.311
资产负债率 (%)33.50932.48030.68426.84515.273
带息债务/全部投入资本 (%)28.94826.61322.86115.2123.570
股东权益/带息债务 (%)238.713266.351321.431529.9792,540.417
股东权益/负债合计 (%)198.315207.878225.906272.510554.820
利息保障倍数 (X)1.077-4.054-7.575-12.943-3.566

营运能力分析
应收账款周转天数 (天)293.397220.014126.01561.82067.053
存货周转天数 (天)207.822155.259126.45481.71580.748